🇺🇸 FDA
Pipeline program

X-82

X82-OPH-201

Phase 2 small_molecule terminated

Quick answer

X-82 for Age-Related Macular Degeneration (AMD) is a Phase 2 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Age-Related Macular Degeneration (AMD)
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials